View in EDS

172P A multi-center, randomized, double-blind, parallel, two-group phase III clinical study on the efficacy and safety of QL1101 or bevacizumab in combination with paclitaxel and carboplatin in the first-line treatment of non-squamous non-small cell lung cancer

Saved in:
Bibliographic Details
Title: 172P A multi-center, randomized, double-blind, parallel, two-group phase III clinical study on the efficacy and safety of QL1101 or bevacizumab in combination with paclitaxel and carboplatin in the first-line treatment of non-squamous non-small cell lung cancer
Authors: Han, B1 (AUTHOR), Li, K2 (AUTHOR), Chu, T1 (AUTHOR), Bi, M3 (AUTHOR), Zhang, H4 (AUTHOR), Yu, Y5 (AUTHOR), Shi, J6 (AUTHOR), Zhang, X7 (AUTHOR), Chen, Z8 (AUTHOR), Han, C9 (AUTHOR), Bai, T9 (AUTHOR)
Source: Annals of Oncology. 2019 Supplement, Vol. 30, pN.PAG-N.PAG. 1p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1093/annonc/mdz063.070